Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

1. (original) A method for treating neoplasia in a mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt thereof.

2. (original) The method of Claim 1 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.

3. (original) A method for treating neoplasia in a subject in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt thereof, wherein the matrix metalloproteinase inhibitor is selected from compounds, and their pharmaceutically acceptable salts thereof, of the group consisting of

1)



N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

2)



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

3)



N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

4)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

5)



N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide;

6)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

7)



N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

8)



N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

9)



British Biotech BB-2516 (Marimastat), N4-[2,2-dimethyl- 1-[(methylamino)carbonyl]propyl]- N1,2 -dihydroxy-3 (2-methylpropyl)-, [2S- [N4(R*),2R*,3S*]]-);

10)



Bayer Ag Bay-12-9566, 4-[(4'-chloro[1,1'- iphenyl]- 4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid;

11)



Agouron Pharmaceuticals AG-3340, N-hydroxy-2,2- dimethyl-4-[[4-(4- pyridinyloxy)phenyl]sulfonyl]- 3-thiomorpholinecarboxamide;

12) CollaGenex Pharmaceuticals CMT-3 (Metastat), 6- demethyl-6-deoxy-4-dedimethylaminotetracycline;

13) Chiroscience D-2163, 2- [1S- ([(2R,S)- acetylmercapto- 5-phthalimido]pentanoyl- L- leucyl)amino- 3- methylbutyl]imidazole;

14)



N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide monohydrochloride;

15)



N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4 (trifluoromethoxy) phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

16)



N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinearboxamide;

17)



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

18)



4-[[4-(cyclohexylthio)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide monohydrochloride;

19)



4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide;

20)



N-hydroxy-4-[[4-(4-methoxyphenoxy)phenyl)sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide;

21)



1-cyclopropyl-4-[[4-[(4-fluorophenyl)thio]phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide;

22)



1-cyclopropyl-N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidinecarboxamide;

23)



tetrahydro-N-hydroxy-4-[[4-(4-pyridinylthio)phenyl]sulfonyl]-2H-pyran-4-carboxamide;

24)



tetrahydro-N-hydroxy-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-2H-pyran-4-carboxamide.

4. (original) A method for treating neoplasia in a mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt thereof, wherein the matrix metalloproteinase inhibitor is selected from compounds, and their pharmaceutically acceptable salts thereof, of the group consisting of

1)



N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

2)



1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

3)



N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

4)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

5)



N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide;

6)



N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

7)



N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

8)



N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

9)



British Biotech BB-2516 (Marimastat), N4-[2,2-dimethyl- 1-[(methylamino)carbonyl]propyl]- N1,2 -dihydroxy-3 (2-methylpropyl)-, [2S-[N4(R*),2R*,3S*]]-);

10)



Bayer Ag Bay-12-9566, 4-[(4'-chloro[1,1'- iphenyl]- 4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid;

11)



Agouron Pharmaceuticals AG-3340, N-hydroxy-2,2- dimethyl-4-[[4-(4- pyridinyloxy)phenyl]sulfonyl]- 3-thiomorpholinecarboxamide;

12) CollaGenex Pharmaceuticals CMT-3 (Metastat), 6-demethyl-6-deoxy-4-dedimethylaminotetracycline; and

13) Chiroscience D-2163, 2- [1S- ([(2R,S)- acetylmercapto- 5- phthalimido]pentanoyl- L- leucyl)amino- 3- methylbutyl]imidazole.

5. – 14. (withdrawn)

15. (original) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



Agouron Pharmaceuticals AG-3340, N-hydroxy- 2,2- dimethyl- 4-[[4-(4- pyridinyloxy)phenyl]sulfonyl]- 3- thiomorpholinecarboxamide.

16.-17. (withdrawn)

18. (canceled)

19. (original) The method of Claim 1 wherein the combination is administered in a sequential manner.

20. (original) The method of Claim 1 wherein the combination is administered in a substantially simultaneous manner.

21. (original) The method of Claim 3 wherein the combination is administered in a sequential manner.

22. (original) The method of Claim 3 wherein the combination is administered in a substantially simultaneous manner.